Cerebrospinal fluid proNGF: A putative biomarker for early alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 7, 2016, Pages 800-808

  Counts, Scott E ^a,b   He, Bin ^c   Prout, John G ^d   Michalski, Bernadeta ^e   Farotti, Lucia ^f   Fahnestock, Margaret ^e   Mufson, Elliott J ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b St Mary's Mercy Medical Center   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d JUNIATA COLLEGE   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alzheimer's disease; Amyloid; Biomarker; Cerebrospinal fluid; Mild cognitive impairment; ProNGF; Tau

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; PROTEIN PRECURSOR; PRO-NERVE GROWTH FACTOR, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; UPREGULATION; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; MENTAL HEALTH; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITIVE DYSFUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NERVE GROWTH FACTOR; PROTEIN PRECURSORS;

EID: 84969917958     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160129095649     Document Type: Article

References (51)

1. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-9 (2011).
2. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58: 397-405 (2001).
3. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-68 (1999).
4. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64: 834-41 (2005).
5. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63: 38-46 (2006).
6. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158: 469-90 (1999).
7. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 22: 312-9 (2006).
8. Weiner MW, Aisen PS, Jack CR, Jr., Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6: 202-11 (2010).
9. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-9 (2007).
10. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-93 (2009).
11. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66: 638-45 (2009).
12. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6: 230-8 (2010).
13. Counts SE, Mufson EJ. Putative CSF protein biomarker candidates for amnestic mild cognitive impairment. Transl Neurosci 1: 2-8 (2010).
14. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6: e16032 (2011).
15. Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 76: 501-10 (2011).
16. Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer's Disease. J Neuropathol Exp Neurol 63: 641-9 (2004).
17. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, et al. Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 71: 1018-29 (2012).
18. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 18: 210-20 (2001).
19. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 294: 1945-8 (2001).
20. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 56: 520-31 (2004).
21. Masoudi R, Ioannou MS, Coughlin MD, Pagadala P, Neet KE, Clewes O, et al. Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J Biol Chem 284: 18424-33 (2009).
22. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, et al. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123: 13-30 (2012).
23. Counts SE, Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 64: 263-72 (2005).
24. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4: 340-50 (2007).
25. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 93: 1412-21 (2005).
26. Michalski B, Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res Mol Brain Res 111: 148-54 (2003).
27. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology 59: 198-205 (2002).
28. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 65: 592-601 (2006).
29. Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry 68: 885-93 (2010).
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984).
31. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82: 239-59 (1991).
32. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8: 1-13 (2012).
33. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-86 (1991).
34. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123: 1-11 (2012).
35. Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 4: e5424 (2009).
36. Kennedy RE, Schneider LS, Cutter GR, Alzheimer's Disease Neuroimaging I. Biomarker positive and negative subjects in the ADNI cohort: clinical characterization. Curr Alzheimer Res 9: 1135-41 (2012).
37. Mashayekhi F, Salehin Z. Cerebrospinal fluid nerve growth factor levels in patients with Alzheimer's disease. Ann Saudi Med 26: 278-82 (2006).
38. Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM, et al. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 54: 2009-11 (2000).
39. Marksteiner J, Pirchl M, Ullrich C, Oberbauer H, Blasko I, Lederer W, et al. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties. Pharmacology 82: 214-20 (2008).
40. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118: 140-6 (2003).
41. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129: 526-9 (2008).
42. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology 70: 2212-8 (2008).
43. Mukaetova-Ladinska EB, Milne J, Andras A, Abdel-All Z, Cerejeira J, Greally E, et al. Alpha-and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. Dement Geriatr Cogn Disord 26: 32-42 (2008).
44. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 58: 748-57 (2005).
45. Iqbal K, Grundke-Iqbal I. Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease. Int Psychogeriatr 9 (1): 289-96; discussion 317-21 (1997).
46. Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener 9: 53 (2014).
47. Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 11(10): 1180-90 (2015).
48. Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Radanovic M, Gattaz WF, et al. Reduced cerebrospinal fluid levels of brainderived neurotrophic factor is associated with cognitive impairment in late-life major depression. J Gerontol B Psychol Sci Soc Sci 69: 845-51 (2014).
49. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20: 415-8 (2014).
50. Fahnestock M, Yu G, Michalski B, Mathew S, Colquhoun A, Ross GM, et al. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem 89: 581-92 (2004).
51. Rattenholl A, Lilie H, Grossmann A, Stern A, Schwarz E, Rudolph R. The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem 268: 3296-303 (2001).